Tagged as: Executive Order

Request for Comments on USPTO-FDA Collaboration Initiatives to Promote Generic Drug and Biosimilar Competition

On November 7, the U.S. Patent and Trademark Office (USPTO) published a request for comments on areas for USPTO-FDA collaboration and engagement. The USPTO also announced a related public listening session to be held on Thursday, January 19, 2023. As we have previously reported, President Biden issued an Executive Order…

Read More

Executive Order for Advancing Biotechnology and Biomanufacturing Innovation Signed by President Biden

On September 12, 2022, President Biden signed the Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy. The objective of the Executive Order is to “coordinate a whole-of-government approach to advance biotechnology and biomanufacturing towards innovative solutions in health, climate change, energy, food…

Read More

President Biden Issues Executive Order Including Provisions To Promote Generic Drug and Biosimilar Competition in the American Economy

On July 9, President Biden issued an Executive Order regarding competition in various sectors of the United States economy, including the healthcare market.  Among the 72 initiatives set forth in the Order are instructions that charge various agencies with tasks to promote generic and biosimilar competition.  The Order directs the Food…

Read More